FMP
NASDAQ
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
2.79 USD
0.02 (0.717%)
Valuation Date:
Apr 24, 2024 3:35 PM
Share Price on Valuation Date
$2.79
Stock Beta
-1.005
Shares Outstanding
25933200